Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72541
Title:
Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.
Authors:
Wilkinson, Peter M; Antonopoulos, M; Lahousen, M; Lind, Michael J; Kosmidis, P
Abstract:
This multicentre, open-label, controlled clinical trial assessed the effects of epoetin alfa treatment on haematologic and quality of life (QOL) parameters in 182 anaemic (Hb< or = 12 g dl(-1)) ovarian cancer patients receiving platinum chemotherapy. Patients were randomised 2 : 1 to receive epoetin alfa 10,000-20 000 IU three times weekly plus best standard treatment (BST) or BST only. Main study end points were changes from baseline in haemoglobin (Hb) level, transfusion requirements, and QOL. For the epoetin alfa group, mean Hb increased by 1.8 g dl(-1) by weeks 4-6 and was significantly increased from baseline through study end (P<0.001). The mean change in Hb from baseline was significantly (P<0.001) greater for epoetin alfa than BST patients at all post-baseline evaluations. Significantly fewer epoetin alfa than BST patients required transfusion(s) after the first 4 weeks of treatment (7.9 vs 30.5%; P<0.001). Also, significant (P< or = 0.04) differences favouring the epoetin alfa group over the BST group were found for all three median CLAS scores (Energy Level, Ability to Do Daily Activities, Overall QOL) and the median average CLAS score during chemotherapy. These findings support use of epoetin alfa to increase Hb levels, reduce transfusion use, and improve QOL in anaemic ovarian cancer patients receiving platinum chemotherapy.
Affiliation:
Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK. peter.wilkinson@christie-tr.nwest.nhs.uk
Citation:
Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. 2006, 94 (7):947-54 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
10-Apr-2006
URI:
http://hdl.handle.net/10541/72541
DOI:
10.1038/sj.bjc.6603004
PubMed ID:
16570051
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWilkinson, Peter M-
dc.contributor.authorAntonopoulos, M-
dc.contributor.authorLahousen, M-
dc.contributor.authorLind, Michael J-
dc.contributor.authorKosmidis, P-
dc.date.accessioned2009-07-06T10:36:42Z-
dc.date.available2009-07-06T10:36:42Z-
dc.date.issued2006-04-10-
dc.identifier.citationEpoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. 2006, 94 (7):947-54 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid16570051-
dc.identifier.doi10.1038/sj.bjc.6603004-
dc.identifier.urihttp://hdl.handle.net/10541/72541-
dc.description.abstractThis multicentre, open-label, controlled clinical trial assessed the effects of epoetin alfa treatment on haematologic and quality of life (QOL) parameters in 182 anaemic (Hb< or = 12 g dl(-1)) ovarian cancer patients receiving platinum chemotherapy. Patients were randomised 2 : 1 to receive epoetin alfa 10,000-20 000 IU three times weekly plus best standard treatment (BST) or BST only. Main study end points were changes from baseline in haemoglobin (Hb) level, transfusion requirements, and QOL. For the epoetin alfa group, mean Hb increased by 1.8 g dl(-1) by weeks 4-6 and was significantly increased from baseline through study end (P<0.001). The mean change in Hb from baseline was significantly (P<0.001) greater for epoetin alfa than BST patients at all post-baseline evaluations. Significantly fewer epoetin alfa than BST patients required transfusion(s) after the first 4 weeks of treatment (7.9 vs 30.5%; P<0.001). Also, significant (P< or = 0.04) differences favouring the epoetin alfa group over the BST group were found for all three median CLAS scores (Energy Level, Ability to Do Daily Activities, Overall QOL) and the median average CLAS score during chemotherapy. These findings support use of epoetin alfa to increase Hb levels, reduce transfusion use, and improve QOL in anaemic ovarian cancer patients receiving platinum chemotherapy.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBlood Transfusion-
dc.subject.meshCisplatin-
dc.subject.meshEpoetin Alfa-
dc.subject.meshFemale-
dc.subject.meshHematinics-
dc.subject.meshHemoglobins-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshQuality of Life-
dc.titleEpoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Wilmslow Road, Manchester M20 4BX, UK. peter.wilkinson@christie-tr.nwest.nhs.uken
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.